Medical Cannabis License Value Just Tripled: The 90-Day Operator Playbook After Schedule III

If you hold a state-issued medical cannabis license, or you have an application sitting in a pipeline anywhere in the United States, your asset just appreciated. On April 22, 2026, the Department of Justice and the DEA moved state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act. Adult-use cannabis stays in Schedule I. This is not a policy paper. This is a balance sheet event.

Medical cannabis license value, which has been depressed for years by Section 280E and federal stigma, just jumped overnight. The operators who recognize it and move in the next 90 days will outperform every operator who waits for the dust to settle.

This post is the Collateral Base operator playbook for the next 90 days: what changes for medical license-holders, what changes for adult-use operators, what to do this week if you have an open license application, and how the M&A market is already pricing the new world.

Why medical cannabis license value just jumped

For the first time in over fifty years, the federal government has moved cannabis on the schedule. The order is narrow. It covers FDA-approved marijuana drug products and “marijuana subject to a state-issued license to manufacture, distribute, and/or dispense for medical purposes only.” But the financial impact for medical-licensed operators is enormous.

Three things changed at once:

1. Section 280E goes away for state-licensed medical activity. 280E denied deductions only for businesses trafficking in Schedule I and Schedule II controlled substances. Schedule III is not on that list. Effective tax rates that ran 60 to 80 percent for years should drop dramatically. Payroll, marketing, rent, professional fees, and software licenses are once again deductible against medical-licensed cannabis revenue.
2. Treasury was directed to consider retrospective relief. The DOJ order asks Treasury to evaluate refunds for prior years of disallowed deductions. Refunds are not granted yet, but the pathway is open and every cannabis CFO is now reviewing 2023, 2024, and 2025 returns for medical-revenue allocation.
3. An expedited DEA registration pathway is being built for medical license-holders. State medical license-holders are not starting from scratch with the federal government. The existing state license is the substantive due-diligence gate, and federal registration is administrative confirmation.

Add it up: a state medical cannabis license is now a recurring revenue asset that throws off normal-economy after-tax margins, with a refund tail for prior years. That is the financial profile the medical license-holders have wanted for a decade. They have it now.

The 90-day operator playbook

The window where preparation produces outsized returns is the next 90 days. Here is the Collateral Base operator playbook for a medical license-holder, an adult-use operator, and a license applicant.

If you hold a state medical cannabis license

1. Run a clean medical revenue allocation by SKU and by storefront. Some of you sell only to medical patients. Some of you operate dual licenses and have always done a back-of-envelope split. Stop. The Schedule III lane only protects revenue and activity that is “subject to a state-issued license to manufacture, distribute, and/or dispense for medical purposes only.” Anything that strays outside the four corners of that license falls back into Schedule I and stays under 280E. Your chart of accounts needs to reflect the two tax regimes by April 30.
2. Preserve every disallowed-deduction workpaper from 2023, 2024, and 2025. Do not file amended returns. Do build the package. The day Treasury publishes retroactive relief guidance, you want to be first in the queue with documentation.
3. Stand up DEA registration readiness. Identify a responsible person, lock down a facility security plan, get recordkeeping and chain-of-custody compliant with DEA expectations, and pre-file as soon as the expedited pathway opens. The first wave of DEA-registered medical cannabis operators will be a marketing asset for years.
4. Reprice your medical menu. Your unit economics changed. The price you charge a medical patient should reflect a real-economy after-tax margin, not a 280E-distorted one. Some of that goes to growth investment, some goes to lower prices, some goes to your shareholders. That’s a strategy decision, not an accounting one.

If you operate adult-use only

1. Decide whether to add a medical line. States with parallel medical programs (Illinois, Michigan, New York, Missouri, Ohio, Maryland, and others) suddenly favor operators who hold both licenses. The medical bolt-on is the fastest way to capture the Schedule III tax benefit.
2. Track the June 29 hearing. The DEA reopened the broader rescheduling proceeding. A new evidentiary hearing begins June 29, 2026. If adult-use also moves to Schedule III before year-end, your tax structure changes. If it does not, the medical-only operators get a 12 to 18 month head start. Plan for both.
3. Re-underwrite your wholesale supply. Wholesale flower and concentrate prices are already compressed. Cultivation closures (PharmaCann’s Colorado exit, 132 layoffs) confirm the trend. Adult-use retailers should be using that to pressure-test their cost of goods.

If you have an open medical cannabis license application

1. Strengthen the medical-license narrative in the application. Whatever you wrote about patient access, vertical integration, and cultivation-to-dispensary chain of custody, go back and put a sharper edge on it. Awarding agencies are paying attention to which operators look ready to move into the Schedule III regime cleanly.
2. Refresh your capital stack. Investors who would not touch a Schedule I cannabis license are taking calls again. Medical cannabis license value at federal Schedule III is a different story for institutional capital. Have your pitch deck ready.
3. Time your closing. If you are mid-application, the closing date matters. Stay disciplined about the regulatory record but understand that a license issued post-April 22 sits inside the Schedule III lane from day one.

How the M&A market is already pricing the new world

The deal market does not wait for academic consensus. In April, Cannabist Co. closed a $130M sale of its Virginia medical operations, a transaction priced before the rescheduling order published, and one that already implied institutional confidence in adult-use upside in Virginia. Expect that valuation pattern to compress: medical-licensed assets in states with adult-use legislation pending will trade at a premium, and the discount that Schedule I status had imposed on cannabis multiples generally is going to ease.

At the same time, the cultivation side of the industry is contracting. PharmaCann is closing its Denver grow operation by May 20 with 132 layoffs. Vireo Growth absorbed Eaze without picking up cultivation. The pattern is consistent: in a wholesale-distressed market, MSOs would rather buy than grow. Cultivators with good soil, good genetics, and a state medical license are now sitting on an asset that is structurally undervalued, and a target for consolidation.

The state-by-state picture matters more than ever

The Schedule III lane is defined by state medical licensing. So the state you operate in suddenly matters more, not less:

• Pennsylvania held a 4/20 testimony hearing on three legalization vehicles. Public support sits at 56 percent. If PA passes adult-use this year, the market dynamics across the entire mid-Atlantic shift.
• Virginia has two competing retail bills. HB 642 targeting a November 1, 2026 launch, and SB 542 pushing it to January 1, 2027. Governor Spanberger picks. The Cannabist transaction shows the market is already pricing in adult-use Virginia.
• Ohio’s SB 56 rolled back the 2023 voter initiative. Existing operators have a real compliance hit. The lesson for every state with a ballot-passed program: lock the language in at constitutional level.
• Rhode Island’s 24-license retail lottery is frozen by federal injunction over a 51 percent residency rule that fails on dormant Commerce Clause grounds. Operators advising on RFP processes everywhere should be running residency provisions through this filter before clients spend money.

Watch this week’s full Cannabis Legalization News breakdown

We covered the rescheduling order, the 280E impact, and the operator playbook in detail on this week’s Cannabis Legalization News show, alongside the SCOTUS argument in United States v. Hemani, the state-by-state legalization fights, the M&A market reset, and Q1 2026 sales data ($6.5B, 4/20 +47%).

👉 Watch the full Cannabis Legalization News show on YouTube, weekly cannabis news, law, and operator analysis from Thomas Howard.

Work with Collateral Base on your Schedule III transition

Collateral Base is the cannabis consulting firm we built for exactly this kind of regulatory inflection. We help operators win licenses, structure dispensary operations, model the new tax economics, and execute the M&A and capital moves that the next 90 days demand.

If you are a medical license-holder, an adult-use operator deciding whether to add a medical line, or an applicant in an open licensing round and you want a partner that has tracked rescheduling from Day One, we should talk.

Get in touch: collateralbase.com

Collateral Base is the cannabis licensing and dispensary operations consultancy founded by Thomas Howard. We do not provide legal, tax, or investment advice. For legal advice on the Schedule III transition, work with a cannabis attorney licensed in your jurisdiction (we know a few good ones at Howard Law Group).